Efficacy and Safety of Antidepressant Drugs in Patients with Dementia

Clinical Trial Report


  1. 1.
    Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic treatment for dementia. Meta-analysis of randomized, placebo-controlled trials. JAMA. 2005;294:1934–43.PubMedCrossRefGoogle Scholar
  2. 2.
    Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Ca Med Assoc J. 2007;176:627–32.CrossRefGoogle Scholar
  3. 3.
    Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry. 2005;66:1090–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008;168:1090–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Kirshner HS. Controversies in behavioral neurology: the use of atypical antipsychotic drugs to treat neurobehavioral symptoms in dementia. Current Neurol Neurosci Rep. 2008;8:471–4.CrossRefGoogle Scholar
  6. 6.
    Schneider LS, Tariot PN, Dagerman PS, et al. for the CATIE-AD Study Group: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355:1525–38.PubMedCrossRefGoogle Scholar
  7. 7.
    Wang PS, Schneeweiss S, Avorn J. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Eng J Med. 2005;353:2335–41.CrossRefGoogle Scholar
  8. 8.
    Dolder C, McKinsey J. Low-dose divalproex in agitated patients with Alzheimer’s disease. J Pschiatr Pract. 2010;16:63–7.CrossRefGoogle Scholar
  9. 9.
    Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2009;8:CD003945.Google Scholar
  10. 10.
    Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer’s disease. Arch Gen Psychiatry. 2011;68:853–61.PubMedCrossRefGoogle Scholar
  11. 11.
    Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54–61.PubMedGoogle Scholar
  12. 12.
    Sommer OH, Aga O, Cvancarova M, et al. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. Dement Geriatr Cogn Disord. 2009;27:155–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer’s disease. Neurology. 2004;63:214–9.PubMedGoogle Scholar
  14. 14.
    Cummings JL, Schneider E, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67:57–63.PubMedCrossRefGoogle Scholar
  15. 15.
    Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007;15:942–52.PubMedCrossRefGoogle Scholar
  16. 16.
    Lebert F, Pasquier F, Petit H. Behavioral effects of trazodone in Alzheimer’s disease. J Clin Psychiatry. 1994;55:536–8.PubMedGoogle Scholar
  17. 17.
    Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55:1271–8.PubMedGoogle Scholar
  18. 18.
    Seitz DP, Adunuri N, Gill SS. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;16:CD008191.Google Scholar
  19. 19.
    Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60:737–46.PubMedCrossRefGoogle Scholar
  20. 20.
    Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010;18:332–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;49:577–85.CrossRefGoogle Scholar
  22. 22.
    Alexopoulos GS, Abrams RC, Young RC, et al. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23:271–84.PubMedCrossRefGoogle Scholar
  23. 23.
    Brodaty H. Antidepressant treatment in Alzheimer’s disease. Lancet. 2011;378:375–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of NeurologyVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations